These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24669387)

  • 41. Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs.
    Doña I; Blanca-López N; Jagemann LR; Torres MJ; Rondón C; Campo P; Gómez AI; Fernández J; Laguna JJ; Rosado A; Blanca M; Canto G
    Allergy; 2011 Nov; 66(11):1428-33. PubMed ID: 21834936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Approval of etoricoxib is unacceptable! Authorised and reimbursed in France, despite an unfavourable risk-benefit balance.
    Prescrire Int; 2010 Aug; 19(108):158. PubMed ID: 20939443
    [No Abstract]   [Full Text] [Related]  

  • 43. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
    Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
    Ponce V; Muñoz-Bellido F; Moreno E; Laffond E; González A; Dávila I
    Contact Dermatitis; 2012 Feb; 66(2):107-8. PubMed ID: 22233472
    [No Abstract]   [Full Text] [Related]  

  • 45. Etoricoxib-induced fixed drug eruption with positive lesional patch tests.
    Calistru AM; Cunha AP; Nogueira A; Azevedo F
    Cutan Ocul Toxicol; 2011 Jun; 30(2):154-6. PubMed ID: 21108578
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiple drug intolerance including etoricoxib.
    Morais-Almeida M; Marinho S; Rosa S; Gaspar A; Rosado-Pinto JE
    Allergy; 2006 Jan; 61(1):144-5. PubMed ID: 16364172
    [No Abstract]   [Full Text] [Related]  

  • 47. Anti-inflammatory and analgesic actions of etoricoxib (an NSAID) combined with misoprostol.
    Moraes BM; do Amaral BC; Morimoto MS; Vieira LG; Perazzo FF; Carvalho JC
    Inflammopharmacology; 2007 Aug; 15(4):175-8. PubMed ID: 17701021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
    Roth-Cline MD
    Circulation; 2006 May; 113(18):2253-9. PubMed ID: 16684875
    [No Abstract]   [Full Text] [Related]  

  • 49. The NSAID roller coaster: more about rofecoxib.
    Aronson JK
    Br J Clin Pharmacol; 2006 Sep; 62(3):257-9. PubMed ID: 16934039
    [No Abstract]   [Full Text] [Related]  

  • 50. Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies.
    Micu MC; Micu R; Ostensen M
    Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1334-8. PubMed ID: 21618455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Few options available for arthritis pain relief. FDA declines to approve Merck's Arcoxia.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(10):1020-2. PubMed ID: 17494894
    [No Abstract]   [Full Text] [Related]  

  • 52. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease.
    Kvasnovsky CL; Aujla U; Bjarnason I
    Scand J Gastroenterol; 2015 Mar; 50(3):255-63. PubMed ID: 25314574
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fixed drug eruption secondary to etoricoxib.
    Rawlings N; Joshi S; Sandison A; Carey B
    Br J Oral Maxillofac Surg; 2024 Jul; 62(6):571-574. PubMed ID: 38816329
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Etoricoxib (Arcoxia)].
    Leclercq P; Malaise MG
    Rev Med Liege; 2004 May; 59(5):345-9. PubMed ID: 15270001
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Concern about one drug or entire class of drugs.
    Curković B
    Reumatizam; 2005; 52(1):5-6. PubMed ID: 16689104
    [No Abstract]   [Full Text] [Related]  

  • 56. COX-2 in play at the AHA and the FDA.
    FitzGerald GA
    Trends Pharmacol Sci; 2007 Jul; 28(7):303-7. PubMed ID: 17573128
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Vioxx fallout.
    Palmer K
    Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592
    [No Abstract]   [Full Text] [Related]  

  • 58. Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis.
    Greenwald M; Peloso PM; Mandel D; Soto O; Mehta A; Frontera N; Boice JA; Zhan XJ; Curtis SP
    Curr Med Res Opin; 2011 Oct; 27(10):2033-42. PubMed ID: 21905970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stroke caused by small vessel occlusion in a patient taking etoricoxib and thalidomide.
    Wong EH; Leung TW; Wong KS
    J Neuroimaging; 2007 Jan; 17(1):87-8. PubMed ID: 17238877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib.
    Schneeweiss S; Glynn RJ; Avorn J; Mamdani M; Mogun H; Solomon DH
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1134-42. PubMed ID: 19844943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.